BCR-ABL1 transcript levels increase in peripheral blood but not in granulocytes after physical exercise in patients with chronic myeloid leukemia

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 71, Issue 1, 2011, Pages 7-11

  Jönsson, Sofia ^a   Olsson, Bob ^a   Jacobsson, Stefan ^a   Palmqvist, Lars ^a   Ricksten, Anne ^a   Ekeland Sjöberg, Kerstin ^a   Wadenvik, Hans ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BCR ABL; Chronic myeloid leukemia; Complete cytogenetic remission; Exercise; Imatinib; Reverse transcriptase polymerase chain reaction

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; IMATINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME INDUCTION; EXERCISE; EXERCISE TEST; FEMALE; GENETIC VARIABILITY; GRANULOCYTE; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MULTINUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; EXERCISE; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; GRANULOCYTES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; RNA, MESSENGER; YOUNG ADULT;

EID: 78651373342     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2010.521981     Document Type: Article

References (17)

1. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelo-cytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977;63:12-30.
2. Nitta M, Kato Y, Strife A, Wachter M, Fried J, Perez A, Jhanwar S, Duigou-Osterndorf R, Chaganti R S, Clarkson B. Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia. Blood 1985;66: 1053-61.
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Effi cacy and safety of a specifi c inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
4. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51.
5. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, Durrant S, Browett P, Schwarer AP, Arthur C, Catalano J, Leahy MF, Filshie R, Bradstock K, Herrmann R, Joske D, Lynch K, Hughes T. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926-32.
6. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008;111:1774-80.
7. Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007;13: 6136-43.
8. Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009;114:2598-605.
9. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi, E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ' real-time ' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia 2003;17:2474-86.
10. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ. Standardization and quality control studies of ' real-time ' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003;17:2318-57.
11. Mishler JM. Hydroxyethyl starch as an experimental adjunct to leukocyte separation by centrifugal means: review of safety and effi cacy. Transfusion 1975;15:449-60.
12. Jonsson S, Olsson B, Ohlsson C, Lorentzon M, Mellstrom D, Wadenvik H. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008;93:1101-3.
13. Gabriel H, Kindermann W. The acute immune response to exercise: what does it mean? Int J Sports Med 1997; 18(Suppl. 1):S28-S45.
14. Gleeson M, Bishop NC. The T cell and NK cell immune response to exercise. Ann Transplant 2005;10:43-8.
15. McCarthy DA, Perry JD, Melsom RD, Dale MM. Leucocy-tosis induced by exercise. Br Med J (Clin Res Ed) 1987; 295:636.
16. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lip-ton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108: 28-37.
17. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Dein-inger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehl-mann R. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108: 1809-20.